PCSK9 and metabolic syndrome: Moreover, we did not provide any information on novel therapeutics, such as proprotein convertase subtilisin/kexin type 9 inhibitors or bempedoic acid, which are paving the way to a novel chapter in the treatment of dyslipidemia.